By Stephen Nakrosis
Avita Medical said the U.S. Food and Drug Administration has approved the company's premarket approval supplement for Recell Go mini, a system to treat smaller wounds.
The Recell Go mini is a line extension of the Recall Go system, and is designed as a treatment for wounds up to 480 square centimeters. The standard Recall Go system treats an area of 1,920 square centimeters, the company said.
Avita said the Recell Go mini can serve as an entry point for clinicians who are unfamiliar with the system, and will allow broader accessibility and use in trauma and burn centers.
Roll out of the Recell Go mini will begin during the first quarter of 2025, the company said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 23, 2024 16:26 ET (21:26 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。